1. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis;Wong;Ophthalmology,2008
2. The burden of age-related macular degeneration: a value-based analysis;Brown;Curr Opin Ophthalmol,2006
3. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters;Elshout;Graefes Arch Clin Exp Ophthalmol,2014
4. Age-related Macular Degeneration: Guidelines for Management;Ophthalmologists Scientific Department, Royal College of Ophthalmologists,2013
5. NICE Appraisal Committee. Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration. NICE technology appraisal guidance 155: National Institute for Health and Care Excellence; 2008. Available at: https://www.nice.org.uk/guidance/ta155. Accessed December 10, 2015.